计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B129259-5mg |
5mg |
现货 ![]() |
| |
| B129259-10mg |
10mg |
现货 ![]() |
| |
| B129259-25mg |
25mg |
现货 ![]() |
| |
| B129259-50mg |
50mg |
期货 ![]() |
| |
| B129259-100mg |
100mg |
现货 ![]() |
|
| 别名 | 比瑞那帕 |
|---|---|
| 英文别名 | 2,2-dimethyl-3-hydroxypropyl 2,2-dimethyl-3-hydroxypropionate | NSC767128 | NSC-767128 | D10417 | HY-16591 | (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]me |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Birinapant |
| 生化机理 | cIAP1(Kd <1 nM)和XIAP(Kd \ xa0 = 45 nM)的有效拮抗剂。不仅与cIAP1,cIAP2,XIAP的分离的BIR3域结合,而且以高亲和力与ML-IAP的单个BIR域结合,并迅速降解结合TRAF2的cIAP1和cIAP2 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | cIAP1/cIAP2 抑制剂 |
| 备注 | 有关更多信息,请参阅SDS。有关溶解度,用法和处理的更多建议?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Birinapant (TL32711) 是一种二价 Smac 模拟物,是 XIAP 和 cIAP1 的强效拮抗剂,Kd 值分别为 45 nM 和小于 1 nM。Birinapant (TL32711) 诱导完整细胞中 cIAP1 和 cIAP2 的自身泛素化和蛋白酶体降解,从而形成 RIPK1: caspase-8 复合物,caspase-8 活化和诱导肿瘤细胞死亡。Birinapant (TL32711) 靶向与 TRAF2 相关的 cIAP,并消除 TNF 诱导的 NF-κB 活化。 |
| 纯度 | ≥98% |
| ALogP | 3.3 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504770943 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide |
| INCHI | 1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1 |
| InChi Key | PKWRMUKBEYJEIX-DXXQBUJASA-N |
| Smiles | CCC(C(=O)N1CC(CC1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)CC6CC(CN6C(=O)C(CC)NC(=O)C(C)NC)O)O)NC(=O)C(C)NC |
| Isomeric SMILES | CC[C@@H](C(=O)N1C[C@H](C[C@H]1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)C[C@@H]6C[C@@H](CN6C(=O)[C@H](CC)NC(=O)[C@H](C)NC)O)O)NC(=O)[C@H](C)NC |
| 分子量 | 806.94 |
| Reaxy-Rn | 36938234 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=36938234&ln= |
| 溶解性 | H2O:<1 mg/mL,Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) |
|---|---|
| 分子量 | 806.900 g/mol |
| XLogP3 | 3.300 |
| 氢键供体数Hydrogen Bond Donor Count | 8 |
| 氢键受体数Hydrogen Bond Acceptor Count | 10 |
| 可旋转键计数Rotatable Bond Count | 15 |
| 精确质量Exact Mass | 806.429 Da |
| 单同位素质量Monoisotopic Mass | 806.429 Da |
| 拓扑极表面积Topological Polar Surface Area | 195.000 Ų |
| 重原子数Heavy Atom Count | 58 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1350.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 8 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
¥576.72
| 1. Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR. (2013) Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.. Breast Cancer Res Treat, 137 (2): (359-71). [PMID:23225169] |
| 2. Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, Villanueva J, Mitsuuchi Y, Neiman EM, Benetatos C et al.. (2013) The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.. Clin Cancer Res, 19 (7): (1784-94). [PMID:23403634] |
| 3. Fulda S. (2014) Molecular pathways: targeting inhibitor of apoptosis proteins in cancer--from molecular mechanism to therapeutic application.. Clin Cancer Res, 20 (2): (289-95). [PMID:24270683] |
| 4. Benetatos CA, Mitsuuchi Y, Burns JM, Neiman EM, Condon SM, Yu G, Seipel ME, Kapoor GS, Laporte MG, Rippin SR et al.. (2014) Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.. Mol Cancer Ther, 13 (4): (867-79). [PMID:24563541] |